An Open-label, Prospective, Non-randomized, Multicenter Study to Evaluate Clear Skin Effect on Health Related Quality of Life Outcomes at 16 and 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis Treated With Secukinumab 300 mg s.c. With or Wit
Read time: 2 mins
Last updated:1st Mar 2016
Primary Sponsor: Novartis Pharmaceuticals
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis patients with or without prior exposure to systemic therapy.
|Date last updated at source||2016-04-22|
|Study start date||2016-03-01|
|Estimated primary completion date||2018-11-01|